Omega 3 supplements may not protect your heart: study



[ad_1]

LONDON: Taking omega 3s through food or supplements is likely to have little or no effect on our risk of suffering from heart disease, stroke or death, a new study which challenges previously held theories.

Increased consumption of omega 3 – a type of fat that is normally found in plant foods such as nuts, rapeseed as well as in oily fish such as salmon and oil of cod liver – is widespread. protect against heart disease.

However, the results, published in the Cochrane Library, showed that the risk of death for any cause was 8.8% in people who had increased their consumption of fatty acids omega 3, compared to 9% among others.

The intake of omega 3 fatty acids (including EPA and DHA), mainly by supplements, has little or no difference with the risk of cardiovascular events, coronary death , coronary artery disease, stroke or heart irregularities.

"We can be confident in the results of this review that go against the popular belief that long-chain omega 3 supplements protect the heart … we do not see Protective effects, "said author Lee Hooper. from East Anglia, United Kingdom.

"The review provides good evidence that taking long-chain omega 3 supplements (fish oil, EPA or DHA) does not benefit heart health or reduce the risk of an accident stroke or death whatever the cause.
[TRADUCTION] "On the other hand, while oily fish is a healthy food, the small number of tests does not determine if eating more oily fish protects our heart," said Hooper.

Eating more ALA – an essential fatty acid and an important part of a balanced diet – through food or supplements probably decreases the risk of heart irregularities from 3.3 to 2 , 6 percent.

However, the reductions are minimal – 143 people should increase their intake of ALA to prevent a person from developing an arrhythmia and 1000 people to prevent a person from dying from coronary artery disease or from being sick. a cardiovascular event, said Hooper.

The study combines the results of seventy-nine randomized trials involving 1,12,059 people from North America, Europe, Australia, and Asia.

[ad_2]
Source link